Zirabev (bevacizumab-bvzr)

Monoclonal antibody

Also known as PF-06439535

Biosimilar of Bevacizumab

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Colorectal Cancer, Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer, Recurrent Glioblastoma, Renal Cell Carcinoma, Cervical Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
US
  • Persistent, Recurrent, or Metastatic Cervical Cancer ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
  • Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ZIRABEV, in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. ZIRABEV, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemothe
Product first approved 2019FDA label
EU
  • Bevacizumab biosimilar (Zirabev): metastatic colorectal, breast, non-squamous NSCLC, renal cell and cervical cancers
Product first approved 2019EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Non-Small Cell Lung Cancer
NCT04325698 · Pfizer
2020-06-11 – 2021-05-10 · Advanced Non-squamous NSCLC
What this study did
Phase 1 (2)
Other / comorbidity
NCT04126044 · Pfizer
2021-01-22 – 2021-07-10 · Pharmacokinetics
What this study did
NCT02031991 · Pfizer
2014-01 – 2014-08 · Healthy
What this study did

Competitive landscape

This mechanism is crowded: 38 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zirabev (bevacizumab-Bvzr): this drugApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Aflibercept (Eylea)
Approved(overall)
Protein / enzyme therapeuticVEGF-A, VEGF-A / VEGF-B / Placental Growth Factor (PlGF)
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Abzv (Enzeevu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Ayyh (Pavblu)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Aflibercept-Boav (Eydenzelt)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Jbvf (Yesafili)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Mrbb (Ahzantive)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept-Yszy (Opuviz)
Approved(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Brolucizumab-Dbll
Approved(overall)
Antibody fragmentVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
Ranibizumab (Lucentis)
Approved(overall)
Antibody fragmentVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Eqrn (Cimerli)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Hkdz (Ranluspec)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Leyk (Nufymco)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab-Nuna (Byooviz)
Approved(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT5906
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
CKD-701 (Lucenbies)
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
HLX04-O
Phase 3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ximluci)
Phase 3(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Surabgene Lomparvovec
Phase 3(overall)
Gene therapy / editingVEGF-A
Weak signal(overall)
No reviewed efficacy summary in this indication
Tarcocimab Tedromer
Phase 3(overall)
Monoclonal antibodyVEGF-A
Reliable signal(overall)
No reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
MW02
Phase 2/3(overall)
Monoclonal antibodyVEGF-A
Partial signal(overall)
No reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication
Ranibizumab (Rimmyrah)
Phase 1(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Afiveg)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Eyluxvi)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Mynzepli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Aflibercept (Vgenfli)
—(overall)
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Ranivisio)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Ranibizumab (Rexatilux)
—(overall)
Monoclonal antibodyVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication
Telbermin
Discontinued
Protein / enzyme therapeuticVEGF-A
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.